Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Amicus Therapeutics' Cash from Investing Activities fell 10379.03% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 136254.55%. This contributed to the annual value of -$560000.0 for FY2024, which is 10057.11% down from last year.
  • Amicus Therapeutics' Cash from Investing Activities amounted to -$1.3 million in Q3 2025, which was down 10379.03% from -$5.8 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Cash from Investing Activities peaked at $86.6 million during Q1 2021, and registered a low of -$68.1 million during Q4 2021.
  • Over the past 5 years, Amicus Therapeutics' median Cash from Investing Activities value was $25.7 million (recorded in 2021), while the average stood at $12.0 million.
  • In the last 5 years, Amicus Therapeutics' Cash from Investing Activities surged by 12244.05% in 2021 and then crashed by 53599.58% in 2025.
  • Amicus Therapeutics' Cash from Investing Activities (Quarter) stood at -$68.1 million in 2021, then rose by 2.03% to -$66.7 million in 2022, then skyrocketed by 64.08% to -$24.0 million in 2023, then rose by 14.88% to -$20.4 million in 2024, then skyrocketed by 93.63% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$5.8 million for Q2 2025, and -$32.9 million during Q1 2025.